obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma
Published 9 years ago • 666 plays • Length 4:10Download video MP4
Download video MP3
Similar videos
-
7:42
obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma
-
7:57
asco 2015: obinutuzumab doubles remission duration in relapsed, indolent non-hodgkin lymphoma
-
1:54
len and obinutuzumab in relapsed indolent lymphoma: improving r2?
-
4:25
obinutuzumab extends remission time in rituximab-refractory inhl
-
1:47
sehn: obinutuzumab doubles pfs in non-hodgkin lymphoma
-
8:07
obinutuzumab plus bendamustine in rituximab-refractory indolent non-hodgkin lymphoma
-
4:50
mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients
-
4:34
obinutuzumab bests rituximab for pfs in follicular lymphoma
-
12:52
debate: is obinutuzumab superior to rituximab in lymphoma? - yes
-
4:42
obinutuzumab extends pfs for follicular lymphoma in gallium trial
-
14:02
debate: is obinutuzumab superior to rituximab in lymphoma? - no
-
5:24
obinutuzumab for indolent lymphoma
-
6:55
robert e. marcus, md: gallium study of obinutuzumab in untreated follicular lymphoma
-
0:51
dr. sehn discusses the gauss obinutuzumab trial
-
4:13
stephen schuster: mosunetuzumab leads to durable complete remissions in non-hodgkin lymphoma
-
2:53
follicular lymphoma: obinutuzumab and chemotherapy
-
18:59
how i approach early relapsing follicular lymphoma
-
0:53
dr. kambhampati on frontline ibrutinib plus obinutuzumab in cll
-
5:44
obinutuzumab/chlorambucil gives os benefit over rituximab in frontline cll